C WorldWide Group Holding A S held its position in Flex Pharma, Inc. (NASDAQ:FLKS) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 278,060 shares of the biotechnology company’s stock at the end of the second quarter. C WorldWide Group Holding A S owned about 1.63% of Flex Pharma worth $1,071,000 at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in FLKS. Primecap Management Co. CA boosted its position in Flex Pharma by 36.0% in the first quarter. Primecap Management Co. CA now owns 1,472,800 shares of the biotechnology company’s stock worth $6,480,000 after buying an additional 390,200 shares in the last quarter. Royce & Associates LP boosted its position in shares of Flex Pharma by 255.1% in the first quarter. Royce & Associates LP now owns 242,200 shares of the biotechnology company’s stock worth $1,066,000 after buying an additional 174,000 shares during the period. Spark Investment Management LLC purchased a new position in shares of Flex Pharma during the first quarter worth approximately $223,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Flex Pharma by 1.2% in the first quarter. Bank of New York Mellon Corp now owns 42,053 shares of the biotechnology company’s stock worth $185,000 after buying an additional 487 shares during the period. Institutional investors and hedge funds own 29.17% of the company’s stock.
Flex Pharma, Inc. (FLKS) opened at 3.22 on Friday. Flex Pharma, Inc. has a 52 week low of $3.01 and a 52 week high of $12.68. The stock has a 50 day moving average price of $3.83 and a 200 day moving average price of $3.92. The stock’s market cap is $55.66 million.
Flex Pharma (NASDAQ:FLKS) last issued its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.51) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.63) by $0.12. Flex Pharma had a negative return on equity of 64.15% and a negative net margin of 2,410.97%. The company had revenue of $0.34 million during the quarter, compared to the consensus estimate of $0.46 million. On average, equities analysts predict that Flex Pharma, Inc. will post ($2.42) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “C WorldWide Group Holding A S Has $1,071,000 Stake in Flex Pharma, Inc. (NASDAQ:FLKS)” was first reported by Stock Observer and is the property of of Stock Observer. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://www.thestockobserver.com/2017/08/12/c-worldwide-group-holding-a-s-has-1071000-stake-in-flex-pharma-inc-nasdaqflks.html.
A number of equities analysts recently commented on the company. Zacks Investment Research upgraded Flex Pharma from a “sell” rating to a “hold” rating in a report on Monday, August 7th. Jefferies Group LLC lowered their target price on Flex Pharma from $9.00 to $8.00 and set a “buy” rating for the company in a report on Thursday, May 4th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $15.40.
About Flex Pharma
Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.
Want to see what other hedge funds are holding FLKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Flex Pharma, Inc. (NASDAQ:FLKS).
Receive News & Ratings for Flex Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.